GlassScriptPhysician profile
Sunil Khanna
NPI 1063404242
$6,647.99
in general payments reported to CMS, 2019-2025
26 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $1,927 · 2021: $1,240 · 2022: $576 · 2023: $818 · 2024: $698 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,162.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,154.35 | 2019-2025 | |
| Welch Allyn | $1,091.71 | 2020 | |
| Janssen Pharmaceuticals, INC | $723.34 | 2019-2024 | Xarelto |
| Amgen INC. | $540.77 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $473.08 | 2019-2025 | Wainua |
| Kowa Pharmaceuticals America, INC. | $351.93 | 2019-2021 | |
| Pfizer INC. | $333.51 | 2019-2024 | |
| Cvrx, INC. | $310.21 | 2021-2025 | Barostim Neo System |
| Novo Nordisk INC | $224.65 | 2021-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $210.26 | 2022-2024 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $188.40 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $183.91 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $127.66 | 2022-2024 | Verquvo |
| Boston Scientific Corporation | $114.77 | 2019-2025 | Watchman Flx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $97.86 | 2019-2021 | |
| Shockwave Medical, INC | $96.63 | 2024 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Abbott Laboratories | $73.67 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $29.23 | 2019 | |
| Exact Sciences Corporation | $21.59 | 2025 | Cologuard Collection Kit |
| Kiniksa Pharmaceuticals International, Plc | $15.29 | 2024 | Arcalyst |
| Lilly USA, LLC | $15.00 | 2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $14.80 | 2024 | Corevalve Evolut R |
| Bridgebio Pharma, INC. | $14.29 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $13.49 | 2025 | Trelegy Ellipta |
| Arbor Pharmaceuticals, INC. | $13.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Khanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.